Harmony Biosciences
HRMY
208 hedge funds and large institutions have $1.64B invested in Harmony Biosciences in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 63 increasing their positions, 81 reducing their positions, and 40 closing their positions.
2.6% more ownership
Funds ownership: 83.69% → 86.29% (+2.6%)
4% more capital invested
Capital invested by funds: $1.58B → $1.64B (+$64.9M)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
6% less funds holding
Funds holding: 221 → 208 (-13)
22% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 81
28% less call options, than puts
Call options by funds: $2.75M | Put options by funds: $3.81M
30% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$40.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$16.1M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
+$8.35M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$7.61M |
| 5 |
CM
Capital Management
Glen Allen,
Virginia
|
+$6.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$41.3M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$24.2M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$8.85M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$4.83M |
| 5 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
-$4.56M |
HRMY Hedge Fund Activity: Q1 2024 in Review
208 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q1 2024, worth a combined $1.64B — up 4.1% from $1.58B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of HRMY and 28 opened new positions — a net loss of 12 holders — while 81 trimmed existing stakes and 63 added.
The largest buyer was Pacer Advisors, adding an estimated $40.8M. The largest seller was Morgan Stanley, cutting an estimated $41.3M.
- 208 institutional investors held Harmony Biosciences (HRMY) as of Q1 2024, down from 221 in Q4 2023.
- Funds reported $1.64B of Harmony Biosciences stock for Q1 2024, up 4.1% quarter-over-quarter.
- 28 funds opened new Harmony Biosciences positions in Q1 2024 and 40 closed out, a net change of -12 holders.
- The largest Harmony Biosciences buyer in Q1 2024 was Pacer Advisors, an estimated $40.8M added.
- The largest Harmony Biosciences seller in Q1 2024 was Morgan Stanley, an estimated $41.3M sold.
Based on aggregated 13F filings for Q1 2024.